relapsing MCD; Hypertension; Condition aggravated; Nausea; Vomiting; Headache; This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MINIMAL LESION (relapsing MCD) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.   LITERATURE REFERENCE: Report of three cases of minimal change disease following the second dose of mRNA SARS-CoV-2 COVID-19 vaccine. Kidney Int Rep. 2021     Concurrent medical conditions included Minimal change disease (biopsy-proven diagnosis of MCD at 9 years of age, which has been in remission since patient was 17 years of age).   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced GLOMERULONEPHRITIS MINIMAL LESION (relapsing MCD) (seriousness criterion medically significant), HYPERTENSION (Hypertension), CONDITION AGGRAVATED (Condition aggravated), NAUSEA (Nausea), VOMITING (Vomiting) and HEADACHE (Headache). At the time of the report, GLOMERULONEPHRITIS MINIMAL LESION (relapsing MCD), HYPERTENSION (Hypertension), CONDITION AGGRAVATED (Condition aggravated), NAUSEA (Nausea), VOMITING (Vomiting) and HEADACHE (Headache) outcome was unknown. Possible    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 1997, Biopsy: minimal change disease (abnormal) Minimal change disease at 9 years of age.. In 2021, Biopsy kidney: minimal change disease (abnormal) Showed features consistent with minimal change disease (MCD). In 2021, Blood albumin: 2.3 g/dl (Low) 2.3 g/dl (hypoalbuminemia). In 2021, Immunology test: normal (normal) showed no evidence of immune complex deposits. In 2021, Microscopy: abnormal (abnormal) showed diffuse effacement of foot processes of podocytes without evidence of immune-type dense deposits. In 2021, Urine protein/creatinine ratio: 6.4 g/g (abnormal) 6.4 g/g (nephrotic-range proteinuria).     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered GLOMERULONEPHRITIS MINIMAL LESION (relapsing MCD), HYPERTENSION (Hypertension), CONDITION AGGRAVATED (Condition aggravated), NAUSEA (Nausea), VOMITING (Vomiting) and HEADACHE (Headache) to be possibly related.    Concomitant medications were not provided.  Microscopic examination by light microscopy of kidney biopsy specimens revealed relatively normal glomeruli.  Treatment information was not reported.  Author concluded that the increasing number of SARS-Cov-2 mRNA vaccine associated MCD cases reported so far suggests  a causal link and warrants careful monitoring in patients with glomerular diseases. An in-depth study of the innate and adaptive immune reactions elicited by SARS-CoV-2 mRNA vaccine might provide a unique opportunity to unravel pathogenic mechanisms responsible for these diseases.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.